Audited by PwC


Novozymes’ stock consists of two types: A and B shares, both with a nominal value of DKK 10 per share. All A common stock is held by Novo A/S, and an A share carries 10 times as many votes as a B share.

A stock B stock Total
Common stock (DKK) 107,487,200 542,512,800 650,000,000
Number of shares 10,748,720 54,251,280 65,000,000
Number of votes 1,074,872,000 542,512,800 1,617,384,800
Voting rights (%) 66.5 33.5 100

Novo A/S holds 25.5% of the total outstanding common stock and, through its holding of the A common stock and a proportion (5,826,280) of the B common stock, controls 70.1% of the votes. Novo A/S is fully owned by the Novo Nordisk Foundation, which is why Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Gladsaxe, Denmark.

At the end of 2008 Novozymes had roughly 53,000 shareholders, of which around 98% are private investors, mainly in Denmark. Thirty institutional shareholders own approximately 52% of the B stock (this includes Novozymes A/S’ holding of treasury stock and Novo A/S’ holding). Investors outside Denmark hold approximately 44%.

Novozymes holds 5.6% of the B stock, equivalent to 4.7% of the total number of shares outstanding.

According to the Danish Companies Act, shareholders must notify the company if they hold at least 5% of the company’s common stock. No shareholders, except Novo A/S, hold more than 5% of Novozymes’ common stock.

Click to see the graph in large format